Unii-7D0yb67S97
|
|
|
- CAS号:
- 332348-12-6
- 英文名:
- Unii-7D0yb67S97
- 英文别名:
- Abatacept;Orencia;CTLA4lg;Ctla4-ig;Bms-188667;Bms 188667;Unii-7D0yb67S97;Research Grade Abatacept;Research Grade Abatacept (DHE03429);1-25-Oncostatin m (human precursor) fusion protein with ctla-4 (antigen) (human) fusion protein with immunoglobulin G1 (human heavy chain fragment), bimol (146-146')-disulfide
- 中文名:
- Unii-7D0yb67S97
- 中文别名:
- 阿巴西普;化合物 T10218
- CBNumber:
- CB62496133
- 分子式:
- 分子量:
- 0
- MOL File:
- Mol file
|
|
|
Unii-7D0yb67S97化学性质
-
储存条件:
-
Store at 4°C, do not freeze
-
|
-
形态:
-
Liquid
-
|
-
颜色:
-
Colorless to light yellow
-
|
-
水溶解性:
-
Soluble in water
-
|
Unii-7D0yb67S97性质、用途与生产工艺
Abatacept (CTLA4lg) 是一种可溶性融合蛋白，由人 CTLA4 的胞外结构域和人 IgG1 Fc 部分的片段 (铰链，CH2 和 3 结构域) 组成。Abatacept 是选择性 T 细胞共刺激调节剂，也是一种用于自身免疫性疾病的蛋白药物。
Abatacept reduces paw edema, and the SC Multiple-dose group shows significantly greater (t
obs
= 2.50) paw edema reduction compared with the IV dose group.
Abatacept exhibits linear PK across the studied doses. The NCA clearance (CL) is 20.8 mL/day/kg, volume (V
ss
) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.
Abatacept (oral; 10 mg/kg; every 2 days) reduces the proportion of activated T cells (CD44highCD62L–) and inhibits the up-regulation of ICOS and CD71 in homozygous DO11.10 RAG-2
–/–
BALB/c (H-2d/d) mice.
|
Animal Model:
|
Male Lewis rats (6-9 weeks old) with weights of 150-175 g
|
|
Dosage:
|
10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29
|
|
Administration:
|
IV or SC
|
|
Result:
|
Reduced paw edema, and the SC Multiple-dose group showed significantly greater (t
obs
= 2.50) paw edema reduction compared with the IV dose group.
|
|
Animal Model:
|
Male Lewis rats (6-9 weeks old) with weights of 150-175 g
|
|
Dosage:
|
10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 (Pharmacokinetic Study)
|
|
Administration:
|
IV or SC
|
|
Result:
|
The NCA clearance (CL) is 20.8 mL/day/kg, volume (V
ss
) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.
|
Unii-7D0yb67S97
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-108829 | Unii-7D0yb67S97
Abatacept | 332348-12-6 | 1mg | 4000元 |
| 2024/04/30 | HY-108829 | Unii-7D0yb67S97
Abatacept | 332348-12-6 | 5mg | 8200元 |
332348-12-6, Unii-7D0yb67S97 相关搜索:
- 药物对照抗体
- 阿巴西普
- 化合物 T10218
- 332348-12-6
- Research Grade Abatacept
- Research Grade Abatacept (DHE03429)
- Orencia
- Abatacept
- CTLA4lg
- Unii-7D0yb67S97
- Ctla4-ig
- Bms-188667
- Bms 188667
- 1-25-Oncostatin m (human precursor) fusion protein with ctla-4 (antigen) (human) fusion protein with immunoglobulin G1 (human heavy chain fragment), bimol (146-146')-disulfide